NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests
Presentation Shows MammaPrint Can Accurately Stratify Recurrence Risk up to 25 Years IRVINE, CA and AMSTERDAM, March 26, 2014 – Four scientific presentations at the 9th European Breast Cancer Conference (EBCC) underscored the international scope Read More
Agendia Co-Founder Awarded EU Prize for Women Innovators
Laura van ‘t Veer, Ph.D., Honored as Inventor of MammaPrint Breast Cancer Test IRVINE, CA and AMSTERDAM, March, 10, 2014 – Agendia co-founder Laura van ‘t Veer, Ph.D., has been awarded a 2014 Read More
Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence
Scientific Poster and Symposium at Miami Breast Cancer Conference Demonstrate Value of MammaPrint and BluePrint Tests Compared to First-Generation Test IRVINE, CA and AMSTERDAM, March, 11, 2014 – A scientific poster comparing Agendia’s MammaPrint® and BluePrint® Read More
Agendia Announces Upcoming Presentation of New Breast Cancer Data on Molecular Subtyping
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 27, 2014– A scientific poster and lunch symposium at the upcoming Miami Breast Cancer Conference will focus new attention on genomic testing and molecular subtyping to refine breast Read More
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Researchers Conclude Molecular Test Is Able to Differentiate High and Low Recurrence Risk up to 25 Years after Diagnosis, Further Validating NEJM Study IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 17,2014 – A newly published Read More
Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference
Next-Generation Genomic Tests Determine Molecular Subtypes and Risk of Recurrence, Providing More Precise Prognosis and Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS, January 30, 2014 – Molecular subtyping provides a more precise prognosis and valuable Read More
Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDs’ Attention on Second-Generation Symphony Suite for Recurrence Risk and Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 23, 2013 – Agendia’s innovations in genomic testing Read More
